3-hydroxybutyric acid and canagliflozin

3-hydroxybutyric acid has been researched along with canagliflozin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Crawford, PA; Goda, M; Iijima, H; Inagaki, N; Maruyama, N; Polidori, D	1
Carria, LR; Galderisi, A; Patel, NS; Sherr, JL; Siebel, S; Tamborlane, WV	1
Baldi, S; Ferrannini, E; Figtree, GA; Hansen, MK; Mahaffey, KW; Neal, B; Perkovic, V; Rosenthal, N; Scozzaro, T; Shaw, W; Tesfaye, F; Tsimihodimos, V	1

Trials

2 trial(s) available for 3-hydroxybutyric acid and canagliflozin

Article	Year
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5 Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biological Variation, Population; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemia; Japan; Ketone Bodies; Male; Reproducibility of Results; Severity of Illness Index; Sex Characteristics; Sodium-Glucose Transporter 2 Inhibitors; Up-Regulation	2018
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes care, 2022, 08-01, Volume: 45, Issue:8 Topics: 3-Hydroxybutyric Acid; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; Glycerol; Heart Failure; Humans; Insulins; Male; Sodium-Glucose Transporter 2 Inhibitors	2022

Article

Year

Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.

Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biological Variation, Population; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemia; Japan; Ketone Bodies; Male; Reproducibility of Results; Severity of Illness Index; Sex Characteristics; Sodium-Glucose Transporter 2 Inhibitors; Up-Regulation

2018

Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).

Diabetes care, 2022, 08-01, Volume: 45, Issue:8

Topics: 3-Hydroxybutyric Acid; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; Glycerol; Heart Failure; Humans; Insulins; Male; Sodium-Glucose Transporter 2 Inhibitors

2022

Other Studies

1 other study(ies) available for 3-hydroxybutyric acid and canagliflozin

Article	Year
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes technology & therapeutics, 2019, Volume: 21, Issue:3 Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Fatty Acids, Nonesterified; Female; Humans; Insulin Aspart; Male; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019